<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799147</url>
  </required_header>
  <id_info>
    <org_study_id>05/16-n</org_study_id>
    <nct_id>NCT02799147</nct_id>
  </id_info>
  <brief_title>GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia</brief_title>
  <official_title>Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several groups have demonstrated very low incidence of acute and chronic graft-versus-host&#xD;
      disease (GVHD) with post-transplantation cyclophosphamide (PTCy) in haploidentical, unrelated&#xD;
      and related allogeneic stem cell transplantation (SCT). Nonetheless for majority of the&#xD;
      grafts, except for 10/10 HLA-matched bone marrow, with this type of prophylaxis require&#xD;
      concomitant administration of calcineurin inhibitors±MMF, which delays immune reconstitution&#xD;
      and development of graft-versus-leukemia (GVL) effect. So, despite reduction of&#xD;
      transplant-related mortality, use of PTCy doesn't lead to the reduction of relapse incidence.&#xD;
      This is particularly important for relapsed or refractory acute leukemia patients, where,&#xD;
      despite all efforts to intensify conditioning regimens, relapses after SCT occur in more than&#xD;
      50% of patients, and long-term survival rarely exceeds 10-20%. In preclinical model of&#xD;
      haploidentical SCT the substitution of post-transplantation cyclophosphamide with&#xD;
      bendamustine, led to comparable GVHD control, but significantly augmented GVL effect. To test&#xD;
      this hypothesis and improve the outcome of allogeneic SCT in refractory acute leukemia&#xD;
      patients we initiated a pilot trial with high-dose post-transplantation bendamustine for GVHD&#xD;
      prophylaxis. The selection of doses is based on the previous dose-escalation studies.&#xD;
      Additional immunosuppression could be added for mismatched grafts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">November 2020</completion_date>
  <primary_completion_date type="Actual">November 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment rate</measure>
    <time_frame>60 days</time_frame>
    <description>Engraftment is defined as the first of 3 consecutive days with an ANC&gt;500 per μl and WBC&gt;1000 per μl. Platelet engraftment is not mandatory for the endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse rate analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GVHD, grades II-IV</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD, moderate and severe (NIH criteria)</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (NCI CTCAE 4.03)</measure>
    <time_frame>100 days</time_frame>
    <description>Toxicity parameters based on NCI CTCAE 4.03 grades: hepatotoxicity (liver function tests), nephrotoxicity (creatinine), neurotoxicity (attending physician assessment), mucositis (attending physician assessment), hemorrhagic cystitis (attending physician assessment), cardiotoxicity (ECG, echocardiography). Additional toxicity parameters: incidence and severity of veno-occlusive disease, incidence of transplant-associated microangiopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious complications, including analysis of severe bacterial, fungal and viral infections incidence</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Leukemia, Acute Lymphoblastic</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Mixed-Lineage Acute Leukemias</condition>
  <arm_group>
    <arm_group_label>280 mg/m2 bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 140 mg/m2/day iv.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg/m2 bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 100 mg/m2/day iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>140 mg/m2 bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3, +4: Bendamustine 70 mg/m2/day iv.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic stem cell transplantation</intervention_name>
    <arm_group_label>140 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>200 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>280 mg/m2 bendamustine</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine monophosphate</intervention_name>
    <arm_group_label>140 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>200 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>280 mg/m2 bendamustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <arm_group_label>140 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>200 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>280 mg/m2 bendamustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <arm_group_label>140 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>200 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>280 mg/m2 bendamustine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Diagnosis: Acute Myeloblastic Leukemia Acute Lymphoblastic Leukemia Mixed-Lineage Acute&#xD;
        Leukemias&#xD;
&#xD;
          -  Disease, refractory to at list one course of induction chemotherapy or immunotherapy&#xD;
&#xD;
          -  More than 5% clonal blasts in the bone marrow or peripheral blood at the time of&#xD;
             inclusion&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Matched related, 8-10/10 HLA-matched unrelated or haploidentical donor available. The&#xD;
             HLA typing is performed by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1,&#xD;
             and HLA-DQB1.&#xD;
&#xD;
          -  No second tumors&#xD;
&#xD;
          -  No severe concurrent illness&#xD;
&#xD;
          -  No previous autologous or allogeneic stem cell transplantations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Karnofsky index &lt;70%&#xD;
&#xD;
          -  Moderate or severe cardiac dysfunction, left ventricular ejection fraction &lt;50%&#xD;
&#xD;
          -  Moderate or severe decrease in pulmonary function, FEV1 &lt;70% or DLCO&lt;70% of predicted&#xD;
&#xD;
          -  Respiratory distress &gt;grade I&#xD;
&#xD;
          -  Severe organ dysfunction: AST or ALT &gt;5 upper normal limits, bilirubin &gt;1.5 upper&#xD;
             normal limits, creatinine &gt;1.5 upper normal limits&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 mL/min&#xD;
&#xD;
          -  Uncontrolled bacterial or fungal infection at the time of enrollment, defined by CRP&#xD;
             level &gt;70 mg/L or positive procalcitonin in patient with adequate empirical&#xD;
             antibacterial and antifungal therapy.&#xD;
&#xD;
          -  Requirement for vasopressor support at the time of enrollment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Somatic or psychiatric disorder making the patient unable to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris V. Afanasyev, Professor</last_name>
    <role>Study Director</role>
    <affiliation>St. Petersburg State Pavlov Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Stokes J, Hoffman EA, Zeng Y, Larmonier N, Katsanis E. Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation. Br J Haematol. 2016 Jul;174(1):102-16. doi: 10.1111/bjh.14034. Epub 2016 Mar 31.</citation>
    <PMID>27030315</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Petersburg State Pavlov Medical University</investigator_affiliation>
    <investigator_full_name>Ivan S Moiseev</investigator_full_name>
    <investigator_title>Vice-director for science of R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation</investigator_title>
  </responsible_party>
  <keyword>Allogeneic Transplantation</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Leukemia, Acute Lymphoblastic</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Mixed-Lineage Acute Leukemias</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Myeloablative Agonists</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Antineoplastic Agents, Alkylating</keyword>
  <keyword>Bendamustine Hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Consultations are ongoing about how IPD initiative fits the local law &quot;About personal data 152-fz&quot;.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

